Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Merck KGaA

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Merck KGaA's 2013 sales performance.

Merck KGaA

Keytruda combo outshines Opdivo in kidney cancer

Keytruda combo outshines Opdivo in kidney cancer

The data sets Merck &Co up to steal market share away from it rival, and the firm has already has filed the combination with the FDA. ... There is another contender in the checkpoint inhibitor field which could play a role: Pfizer and Merck KGaA’s

Industry aghast as EU Parliament backs biosimilar rule change

Industry aghast as EU Parliament backs biosimilar rule change In an open letter to European institutions, the president of the EFPIA trade body, Merck KGaA chairman and CEO Stefan Oschmann (below), says the EP’s provisions “diverge significantly from the

Advair generics and acquisitions to hit GSK in 2019

Advair generics and acquisitions to hit GSK in 2019 Earnings to decline as company transforms. GlaxoSmithKline yesterday demonstrated a new boldness in its business development, signing a multi-billion dollar alliance with Germany’s Merck on next-generation immunotherapy. ... acquisition of Tesaro and

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

BMS CEO tackles investor ‘frustrations’ on immuno-oncology BMS was the pathfinder for the checkpoint inhibitor market with its CTLA4 inhibitor Yervoy (ipilimumab) and PD-1 blocker Opdivo (nivolumab), However, it has since lost ground to rival Merck ... And in the meantime, Opdivo/Yervoy’s lucrative position in

Keytruda hits survival targets in first-line kidney cancer

Keytruda hits survival targets in first-line kidney cancer New data presented at ESMO congress. Merck &Co could steal the thunder of its German namesake Merck KGaA after reporting strong survival data for Keytruda in front-line renal cell carcinoma, ... MSD says Keytruda is the first anti-PD-1 drug to improve

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics